相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recent advances in medical management of hepatocellular carcinoma
Kenji Ikeda
HEPATOLOGY RESEARCH (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma
Atsushi Yukimoto et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
Sadahisa Ogasawara et al.
INVESTIGATIONAL NEW DRUGS (2018)
Chemotherapy for hepatocellular carcinoma: current status and future perspectives
Masafumi Ikeda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy
Takeshi Terashima et al.
HEPATOLOGY RESEARCH (2018)
Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice
Shinsuke Uchikawa et al.
HEPATOLOGY RESEARCH (2018)
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
Richard S. Finn et al.
JOURNAL OF HEPATOLOGY (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment
Teiji Kuzuya et al.
ONCOLOGY (2018)
Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment
Fabio Piscaglia et al.
LIVER CANCER (2018)
Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma
Masatoshi Kudo
LIVER CANCER (2018)
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
Masatoshi Kudo
CANCERS (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis
Atsushi Hiraoka et al.
DIGESTIVE DISEASES (2017)
Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma
Chloe Sauzay et al.
CLINICA CHIMICA ACTA (2016)
Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib
Sadahisa Ogasawara et al.
INVESTIGATIONAL NEW DRUGS (2016)
Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma
Teiji Kuzuya et al.
ONCOLOGY (2016)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2015)
Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma
Teiji Kuzuya et al.
PLOS ONE (2015)
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
Yu-Yun Shao et al.
JOURNAL OF HEPATOLOGY (2014)
Early Decrease in alpha-Fetoprotein, but Not Des-gamma-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
Teiji Kuzuya et al.
ONCOLOGY (2011)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
分享论文
